Prominent psychedelic scientists from across the globe will gather in the Netherlands for the Interdisciplinary Conference on Psychedelic Research 2020. ICPR is the fourth international scientific conference on research into psychedelics organized by the Dutch OPEN Foundation.
Whether you are a therapist or healing practitioner looking for novel modalities, a microdoser, or a curious explorer, you are probably aware of the potential of psychedelics. This conference offers a unique opportunity to meet hundreds of people who are contributing to this cutting-edge field of science of Psychedelics in general.
ICPR hosts lectures, panel discussions, poster presentations, and practically oriented workshops for therapists, researchers and clinicians – focusing on psychology, neuroscience, anthropology and psychiatry.
ICPR 2020 is an ambitious academic conference focused on high-quality scientific research into all aspects of psychedelics and the psychedelic experience. It aims to present the state of the art research findings and facilitate a dialogue between diverse academic fields involved in the study of psychedelics.
What to expect on ICPR?
Featured prominently at ICPR will be the latest findings from clinical research into psychedelics as treatments for mental and other disorders. ICPR also features cutting edge brain imaging research, and the latest findings from psychopharmacology and neurobiology studies. The conference will dedicate ample time for studies from the humanities: anthropological research, ethnographies, social sciences studies, historical research, and philosophical questions. Further, the conference will facilitate in-depth discussions about (psycho)therapeutic frameworks, reflections on therapeutic modalities, and mechanisms of change.
Microdosing, a prominent topic
Alongside the long list of Psychedelic researchers, no less than 6 researchers will be presenting their microdosing research findings. We’ll highlight the talks that have been confirmed so far below. For more information about all other psychedelic researchers, please check this link.
Since the early days of Microdosing.nl, we’re collaborating with many researchers. A big part of this platform’s mission is to advance science-supported insight into microdosing, and bringing these insights back to the microdosers and those who are considering to try microdosing. This is why our team is extremely passionate about this international conference.
James Fadiman & Sophia Korb
Microdosing: Unexpected results of crowd-sourced research: medical, social, scientific. Implications of widespread use.
Microdosing psychedelics (primarily LSD and psilocybin) have had considerable media attention. However, the idea of microdosing dates back to a neglected suggestion by Albert Hoffman. We have been involved, both in supporting and reporting on the recent trend. As microdosing first emerged, we asked the psychedelics communities to let us know about their own experiences. Letters, hand-written journals, emails, and even art poured in. We found ways to systematize what we were learning, and then to ask basic scientifically useful questions, revising our ways of asking as we went.
Beyond the placebo? An exploration of microdosing with self-blinding methodology
Anecdotal reports indicate that microdosing may have benefits in the domains of well-being, productivity and creativity. These anecdotes are compelling, but they are likely to be biased by the placebo effect. Crucially, microdosing includes multiple factors that can lead to a strong placebo response. These factors include, the minimal dose, the subjective character of the benefits and that microdosers are a self-selected community with optimistic attitude towards microdosing. Given these factors, it is likely that placebo-like expectations are at least partially explain the reported benefits.
Cognitive and subjective effects of different low ‘micro’ doses of LSD in a placebo-controlled study
A placebo-controlled within-subjects study including 24 healthy recreational drug users was set up to test the acute effects of three different microdoses of LSD (5, 10, and 20 mcg, p.o.) compared to placebo on measures of cognition (attention) and subjective experience (mood).
Results: The highest dose (20 mcg) significantly enhanced attention and increased self-rated positive mood and happiness while impairing performance of a more complex shifting task and decreasing self-rated levels of concentration and productivity compared to placebo. The intermediate (10 mcg) dose increased the feeling of productivity. Participants noticed they were under the influence of LSD after the high and intermediate microdose and a slight increase in the psychedelic state was experienced.
Microdosing Results from the Global Drug Survey 2019
Objectives: this pre-registered observational study examined a population of microdosers as part of the most recent Global Drug Survey. Results: some of our hypothesized benefits and drawbacks were supported by the data. The three most commonly reported benefits were improved mood, creativity and energy. The three most commonly reported drawbacks were none (i.e., no drawback), confusion, and reduced energy. As we hypothesized, most psychedelics users reported not testing their substances, but a surprisingly large proportion did test their substances. Finally, contrary to our hypothesis, approach-motivation to microdosing was predictive of fewer benefits than avoidance-motivation.
Introduction to the pharmacodynamics of repeated psychedelic-drug intake.
Once-in-a-while” is usually the preferred pattern of intake for users seeking full-dose psychedelic experiences. However, with the recent emergence of the so-called “microdosing” regimen (i.e., the chronic intake of low doses of psychedelics every other day), things have changed raising questions about the consequences of such frequent intake-patterns. In my talk, we will go through basic concepts of psychedelic pharmacodynamics and discuss why it is important to factor in parameters, such as the receptor binding preferences of a psychedelic, when considering the (safety) implications of its chronic (low-dose) intake.
Michiel van Elk
More info to be announced.
More info & tickets
FRIDAY 24 APRIL
Room 1 & 2: Conference
Room 3: Psychiatry Symposium
SATURDAY 25 APRIL
Room 1 & 2 & 3: Conference
SUNDAY 26 APRIL
Room 1 & 2 & 3: Conference
Accreditation for this conference has been requested at NVvP, FGzPT and VVGN.
Tuesday 21 April – Psychedelics for Clinicians 101
Wednesday 22 April – Psychedelics for Clinicians 101
Wednesday 22 April – Microphenomenology
Thursday 23 April – Music in psychedelic therapy
Thursday 23 April – Clinical applications – advanced workshop